8-K: Altimmune Reports Q4/FY25 Results, MASH Phase 3 & FDA Breakthrough

Altimmune, Inc. announced its fourth quarter and full-year 2025 financial results, highlighted by positive MASH trial data, FDA Breakthrough Therapy Designation, and plans for a Phase 3 MASH trial in 2026.

Summary

• Altimmune reported a net loss of $27.4 million, or $0.27 per share, for the fourth quarter ended December 31, 2025.
• The full-year 2025 net loss was $88.1 million, or $1.00 per share.
• Cash, cash equivalents, and short-term investments totaled $274 million as of December 31, 2025.
• The company's balance sheet was further strengthened to approximately $340 million in cash and cash equivalents as of February 28, 2026, following a $75 million registered direct offering and an additional $8 million from an At-the-Market (ATM) facility in January 2026.
• Pemvidutide was granted FDA Breakthrough Therapy Designation for Metabolic Dysfunction-Associated Steatohepatitis (MASH) based on 24-week data from the IMPACT trial.
• Positive 48-week data from the IMPACT Phase 2b trial in MASH showed statistically significant improvements in key non-invasive markers of fibrosis and inflammation, such as Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM), with continued reductions from the 24-week timepoint.
• The company plans to initiate a global Phase 3 registrational trial for pemvidutide in MASH in 2026, with alignment on trial design confirmed with the FDA.
• Topline data from the RECLAIM Phase 2 trial of pemvidutide in Alcohol Use Disorder (AUD) is expected in the third quarter of 2026, with enrollment completed ahead of schedule in November 2025.
• The RESTORE Phase 2 trial of pemvidutide in Alcohol-associated Liver Disease (ALD) is continuing to enroll patients.
• Jerry Durso was appointed Chief Executive Officer, bringing over 30 years of life sciences executive experience.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, driven by the FDA Breakthrough Therapy Designation for MASH, robust 48-week Phase 2b data, and a significantly strengthened balance sheet, all of which de-risk future development and enhance market positioning.

Positives

• Pemvidutide received FDA Breakthrough Therapy Designation for MASH, indicating its potential for substantial improvement over available therapies for a serious condition.
• Positive 48-week data from the IMPACT Phase 2b trial in MASH demonstrated statistically significant improvements in non-invasive markers of fibrosis and inflammation (ELF, LSM) and continued weight loss without evidence of plateau.
• Greater adherence to pemvidutide treatment was observed in trials, attributed to its favorable safety and tolerability profile.
• Successful End-of-Phase 2 Meeting with the FDA confirmed alignment on the Phase 3 registrational trial design for MASH.
• The company's cash, cash equivalents, and short-term investments significantly increased to $274 million by December 31, 2025, and further to $340 million by February 28, 2026, providing a strong financial foundation.
• Enrollment for the RECLAIM Phase 2 AUD trial was completed several months ahead of schedule, signaling significant interest from patients and providers.
• Net loss per share improved to $1.00 for the full year 2025, compared to $1.34 for the full year 2024.

Negatives

• Net loss for the fourth quarter of 2025 increased to $27.4 million from $23.2 million in the same period in 2024.
• General and administrative (G&A) expenses significantly increased to $10.5 million in Q4 2025 from $5.1 million in Q4 2024, primarily due to additional professional fees and compensation expenses, including a one-time stock compensation and payroll-related expense of approximately $2.6 million.
• Full-year G&A expenses also rose to $28.1 million in 2025 from $21.0 million in 2024, partly due to a one-time executive transition cost.

Risks

• Delays in regulatory review processes.
• Interruptions in manufacturing and supply chains.
• Challenges in accessing clinical sites for trials.
• Difficulties in patient enrollment for ongoing and future clinical trials.
• Adverse effects on healthcare systems and disruption of the global economy.
• Uncertainty regarding the reliability of human safety study results and potential adverse effects from product candidates.
• The company's ability to manufacture clinical trial materials on anticipated timelines.
• The success of future product advancements, including the outcomes of future clinical trials.
• The prospects for receiving regulatory approval or successfully commercializing or selling any product or drug candidates.

Future Outlook

Altimmune plans to initiate a global Phase 3 registrational trial for pemvidutide in MASH in 2026, evaluating multiple doses over a 52-week treatment period with biopsy-based endpoints to support potential accelerated approval. The company has also submitted a request for scientific advice to European regulators. Topline data from the RECLAIM Phase 2 trial in Alcohol Use Disorder (AUD) is expected in the third quarter of 2026, and the RESTORE Phase 2 trial in Alcohol-associated Liver Disease (ALD) is continuing to enroll patients.

Management Comments

• "In pemvidutide, we have a unique and differentiated compound with the potential to address critical unmet needs of patients with serious liver diseases such as MASH." Jerry Durso, President and Chief Executive Officer.
• "We are committed to taking the necessary steps to realize its value for all of our stakeholders and have significantly progressed our efforts to strengthen our financial and operational foundation." Jerry Durso.
• "We remain focused on ensuring that we have the means and the capabilities to successfully execute Phase 3 development in MASH and capture the significant opportunities ahead of us." Jerry Durso.
• "We have a number of important inflection points in 2026, most notably the upcoming initiation of our Phase 3 trial of pemvidutide in MASH, for which we are actively finalizing the study plan." Jerry Durso.
• "Finally, we look forward to the topline data from our RECLAIM Phase 2 trial of pemvidutide in AUD, which we expect to release in the third quarter." Jerry Durso.

Industry Context

StockSavvy.ai notes that the MASH treatment landscape is highly competitive, with several companies vying for first-in-class or best-in-class therapies. Altimmune's pemvidutide, with its balanced glucagon/GLP-1 dual receptor agonist activity and FDA Breakthrough Therapy Designation, positions it as a significant contender, especially given the positive 48-week Phase 2b data showing improvements in fibrosis markers and sustained weight loss. The early completion of enrollment for the AUD trial also highlights the substantial unmet need and market interest in new treatments for alcohol use disorder.

Comparison to Industry Standards

• Pemvidutide's Breakthrough Therapy Designation for MASH places it among a select group of therapies recognized by the FDA for their potential to offer substantial improvement over existing treatments for serious conditions. This designation is comparable to those received by other leading MASH candidates, such as Madrigal Pharmaceuticals' resmetirom, which also received Breakthrough Therapy Designation and subsequently gained accelerated approval.
• The observed statistically significant improvements in non-invasive markers of fibrosis (ELF, LSM) at 48 weeks for pemvidutide are critical, as these markers are strongly associated with MASH histologic changes. This data builds upon earlier positive MASH resolution and fibrosis trends, aligning with the rigorous efficacy benchmarks set by other advanced MASH programs.
• The sustained weight loss observed with pemvidutide, with no evidence of plateau at 48 weeks, is a key differentiator in the metabolic disease space, where many GLP-1 agonists show weight loss, but the dual action of pemvidutide may offer a more comprehensive metabolic benefit relevant to MASH pathology.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical progress (Breakthrough Therapy Designation, positive Phase 2b data), strengthened financial position, and clear path to Phase 3, potentially increasing shareholder value.
• Patients (MASH, AUD, ALD): Potential for a new, effective treatment option (pemvidutide) for serious liver diseases and alcohol use disorder, offering hope for improved health outcomes.
• Employees: Stable outlook with continued development activities and a strengthened financial foundation, potentially leading to growth opportunities.
• Regulatory Authorities: Continued engagement with FDA (Breakthrough Therapy Designation, End-of-Phase 2 meeting) and European regulators, indicating adherence to regulatory processes.

Next Steps

• Initiation of global Phase 3 registrational trial of pemvidutide in MASH in 2026.
• Finalizing the study plan for the Phase 3 MASH trial.
• Submission of request for scientific advice to European regulators for MASH.
• Expectation of topline data from RECLAIM Phase 2 trial of pemvidutide in AUD in Q3 2026.
• Continued enrollment in RESTORE Phase 2 trial of pemvidutide in ALD.

Key Dates

Recommendation

The FDA Breakthrough Therapy Designation for pemvidutide in MASH, coupled with compelling 48-week Phase 2b data showing significant improvements in key liver health markers and sustained weight loss, substantially de-risks the development pathway and highlights the drug's potential. The company's strengthened cash position, bolstered by recent capital raises, provides a solid financial runway for the upcoming Phase 3 trial. These factors, combined with the positive progress in AUD and ALD programs, indicate strong momentum and significant upside potential for investors.

Keywords

Altimmune, pemvidutide, MASH, AUD, ALD, biopharmaceutical, Phase 3 trial, Breakthrough Therapy Designation, financial results, clinical trials, liver disease, GLP-1, glucagon, weight loss